Screening, Brief Intervention, and Referral to Treatment for Offenders (SBIRT)

This study is currently recruiting participants.
Verified March 2013 by University of California, Los Angeles
Sponsor:
Collaborators:
Homeless Health Care
Los Angeles Sheriff's Department
Information provided by (Responsible Party):
Michael Prendergast, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT01683643
First received: September 5, 2012
Last updated: March 8, 2013
Last verified: March 2013
  Purpose

The purpose of the study is to determine whether SBIRT is an effective intervention with inmates and to estimate the costs of providing SBIRT to this population.


Condition Intervention
Substance Use
HIV Infections
Behavioral: SBIRT
Behavioral: Control Group

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Screening, Brief Intervention, and Referral to Treatment for Offenders

Resource links provided by NLM:


Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • A reduction in the use of drugs and alcohol [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Participation in treatment [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Rearrest and incarceration [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • A reduction in HIV risk behaviors [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • The cost benefit of SBIRT for offenders [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 800
Study Start Date: April 2012
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SBIRT Group
Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles.
Behavioral: SBIRT
Screening, brief intervention, and referral to treatment.
Active Comparator: Control Group
Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
Behavioral: Control Group
Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.

Detailed Description:

Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based practice that has been found to be effective in reducing alcohol and illicit drug use, mainly among persons recruited in medical centers, primary care offices, emergency rooms, and colleges and universities. But SBIRT has the potential to be applicable to other populations that have, or that are at risk for, substance use problems. In particular, offenders have high prevalence of drug and alcohol use at varying levels of severity and often do not receive adequate intervention, either because of limited availability of programs, low motivation, or lack of awareness of the consequences of their substance use.

The scientific aims of the study are:

  1. Assess the effectiveness of SBIRT with offenders in terms of participation in brief intervention (if so indicated) and enrollment in treatment (if so indicated).
  2. Assess the effectiveness of SBIRT with offenders in terms of drug use, criminal activity, and criminal justice involvement at 12 months following baseline.
  3. Determine whether there are differences in acceptability, participation, and outcomes between men and women.
  4. Determine the cost of providing the SBIRT intervention with this population.

The clinical aims of the study are:

  1. To complement the use of SBIRT within Los Angeles County's substance abuse treatment system.
  2. To expand prevention and treatment options for offenders with substance abuse problems.

To our knowledge, this would be the first rigorous test of SBIRT with an offender population.

We will recruit inmates at two Los Angeles County Sheriff jail facilities, one for men and one for women (25% of total sample), and randomly assign them to the treatment (SBIRT) group (N =400) or to the control (no intervention) group (N = 400). Baseline demographic data will be collected. Subjects in both groups will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles. Twelve months after study admission, all study participants will be contacted for a follow-up interview. We will obtain records-based data on arrests and jail incarceration over the follow-up period from the Sheriff's Department and the California Department of Justice. We will also collect subject participation in publicly-funded treatment from the Substance Abuse Prevention and Control Division of the Los Angeles County Department of Health.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The sample for the study will be drawn from an offender population who are within 2-3 weeks of their release from MCJ or CRDF in Los Angeles County. In addition, subjects must be:

    • At least 18 years of age
    • English or Spanish speaking
    • Not subject to extended jail or prison sentence
    • Able to provide informed consent to participate in the study

Exclusion Criteria:

  • Study exclusion criteria:

    • Inability to provide informed consent to study participation because of cognitive impairment.
    • Inability to communicate in either English or Spanish
    • Refusal to complete Locator form for follow-up.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01683643

Contacts
Contact: Michael Prendergast, Ph.D (310) 267-5503

Locations
United States, California
University of California Recruiting
Los Angeles, California, United States, 90025
Sponsors and Collaborators
University of California, Los Angeles
Homeless Health Care
Los Angeles Sheriff's Department
Investigators
Principal Investigator: Michael Prendergast, Ph.D UCLA Integrated Substance Abuse Programs
Study Director: Jerry Cartier, M.A. UCLA Integrated Substance Abuse Programs
  More Information

No publications provided by University of California, Los Angeles

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Michael Prendergast, Principal Investigator, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01683643     History of Changes
Other Study ID Numbers: R01DA031879
Study First Received: September 5, 2012
Last Updated: March 8, 2013
Health Authority: United States: National Institute on Drug Abuse

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on April 17, 2014